Summary:
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerabilitys of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma. The purpose of this study is to evaluate dexpramipexole as an add-on therapy in participants with inadequately controlled eosinophilic asthma. The study will also further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Criteria:- Male or female > 12 years of age at Screening visit 1
- Documented physician diagnosis of asthma for > 12 months prior to Screening visit 1
- Use of a corticosteroid inhaler as well as a second asthma medication that can be an inhaler or oral medication
- Smoking within 12 months is not prohibited
Qualified Participants May Receive:
Dexpramipexole tablets for oral use or placebo